Drug Trial Radar · NCT03899155
Pan Tumor Rollover Study
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
Aug 9, 2019
Primary completion
Aug 25, 2029
Study completion Aug 25, 2029
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Exelixis; Novartis; Clovis Oncology, Inc.; Janssen Pharmaceuticals
- First posted
- Apr 2, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Conditions
- Cancer
Interventions
NivolumabDrug
Specified dose on specified days
IpilimumabDrug
Specified dose on specified days
CabozantinibDrug
Specified dose on specified days
TrametinibDrug
Specified dose on specified days
RelatlimabDrug
Specified dose on specified days
Nivolumab + RelatlimabDrug
Specified dose on specified days
CapecitabineDrug
Specified dose on specified days
BevacizumabDrug
Specified dose on specified days
TemozolomideDrug
Specified dose on specified days
RucaparibDrug
Specified dose on specified days
DaratumumabDrug
Specified dose on specified days
RegorafinibDrug
Specified dose on specified days
LeucovorinDrug
Specified dose on specified days
FluorouracilDrug
Specified dose on specified days
OxaliplatinDrug
Specified dose on specified days
EnzalutamideDrug
Specified dose on specified days
SunitinibDrug
Specified dose on specified days
PemetrexedDrug
Specified dose on specified days
PembrolizumabDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: From Day 1 up to 135 Days after discontinuation of treatment
- Incidence of drug related AEsTime frame: From Day 1 up to 135 Days after discontinuation of treatment
- Incidence of AEs leading to DiscontinuationTime frame: From Day 1 up to 135 Days after discontinuation of treatment
- Incidence of Serious Adverse Events (SAEs)Time frame: From signature of Informed Consent up to 135 Days after discontinuation of treatment
- Incidence of Select AEsTime frame: From Day 1 up to 135 Days after discontinuation of treatment
- Incidence of Immune-Mediated AEsTime frame: From Day 1 up to 135 Days after discontinuation of treatment
- Incidence of DeathTime frame: From signature of Informed Consent up to 135 Days after discontinuation of treatment
Locations
410 sites in 38 countries. Site status is shown where the registry gives one.
Local Institution - 0220
Huntsville, Alabama · Completed
University of Arizona College of Medicine
Tucson, Arizona · Withdrawn
Innovative Clinical Research Institute
Lynwood, California · Withdrawn
Local Institution
San Francisco, California · Withdrawn
Local Institution - 0099
San Francisco, California · Completed
Local Institution - 0233
Aurora, Colorado · Completed
Local Institution - 0095
New Haven, Connecticut · Withdrawn
Local Institution - 0088
Washington D.C., District of Columbia · Completed
Florida Cancer Affiliates
Ocala, Florida · Withdrawn
Local Institution
Orlando, Florida · Withdrawn
Local Institution - 0024
Tampa, Florida · Completed
Local Institution - 0105
Chicago, Illinois · Completed
Local Institution
Maywood, Illinois · Withdrawn
Local Institution - 0279
Park Ridge, Illinois · Completed
Local Institution - 0186
Westwood, Kansas · Completed
Local Institution - 0165
Wichita, Kansas · Completed
University of Louisville-James Graham Brown Cancer Center
Louisville, Kentucky · Recruiting
Local Institution - 0092
Baltimore, Maryland · Completed
Local Institution - 0039
Boston, Massachusetts · Completed
Dana_Farber Cancer Institute (DFCI)
Boston, Massachusetts · Recruiting
Local Institution - 0081
Boston, Massachusetts · Withdrawn
Local Institution - 0143
Ann Arbor, Michigan · Completed
Local Institution - 0100
Minneapolis, Minnesota · Completed
Local Institution
St Louis, Missouri · Withdrawn
Local Institution - 0205
Omaha, Nebraska · Completed
Local Institution - 0014
Lebanon, New Hampshire · Completed
Local Institution
Albuquerque, New Mexico · Withdrawn
Local Institution - 0128
Buffalo, New York · Completed
NYU Langone Hematology Oncology Associates-Mineola
Mineola, New York · Recruiting
Local Institution
New York, New York · Withdrawn
Local Institution - 0185
New York, New York · Completed
Local Institution - 0202
New York, New York · Withdrawn
Local Institution
New York, New York · Withdrawn
Local Institution - 0204
Charlotte, North Carolina · Completed
Local Institution - 0016
Durham, North Carolina · Completed
Oncology Hematology Care
Cincinnati, Ohio · Recruiting
Local Institution - 0408
Cincinnati, Ohio · Completed
Local Institution
Cleveland, Ohio · Withdrawn
The Ohio University
Columbus, Ohio · Recruiting
Local Institution - 0246
Tulsa, Oklahoma · Withdrawn
Showing 40 of 410 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.